Boehringer Ingelheim has announced a new drug delivery research partnership with the UK-based exosome therapy firm Evox Therapeutics.
The research collaboration will see the companies working to investigate exosome-mediated delivery of RNAs with high medical relevance to specific disease targets that Boehringer Ingelheim will select.
“Boehringer Ingelheim is partnering with Evox Therapeutics on the development of new exosome-mediated drug delivery methods.“
Exosomes are small, cell-derived vesicles that can be combined with highly specific targeting technology to enable the development of natural delivery nanoparticles for the treatment of severe diseases.
Evox and Boehringer Ingelheim will carry out comprehensive in vitro and in vivo research using Evox's exosome technology in return for undisclosed financial considerations, with Boehringer Ingelheim having the option to negotiate a licence agreement to further the develop RNA drug candidates.
Dr Antonin de Fougerolles, chief executive officer of Evox, said: "We look forward to working with Boehringer Ingelheim to evaluate the potential of exosomes to deliver drugs to sites that are currently inaccessible by other means."
This collaboration is part of Boehringer Ingelheim's Research Beyond Borders initiative, which aims to explore emerging science and technologies beyond its core therapeutic areas, creating new opportunities in disease indications of high medical need.
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical